• Je něco špatně v tomto záznamu ?

Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study

D. Vinereanu, D. Napalkov, J. Bergler-Klein, B. Benczur, M. Ciernik, N. Gotcheva, A. Medvedchikov, P. Põder, D. Simić, A. Skride, W. Tang, M. Trusz-Gluza, J. Vesely

. 2021 ; 52 (4) : 1195-1206. [pub] 20210430

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012006

Grantová podpora
N/A Boehringer Ingelheim GmbH

E-zdroje Online Plný text

NLK ProQuest Central od 1998-06-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2011-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1998-06-01 do Před 1 rokem

Odkazy

PubMed 33929686
DOI 10.1007/s11239-021-02450-2
Knihovny.cz E-zdroje

BACKGROUND: The oral anticoagulant dabigatran offers an effective alternative to vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF), yet patient preference data are limited. The prospective observational RE-SONANCE study demonstrated that patients with AF, newly initiated on dabigatran, or switching to dabigatran from long-term VKA therapy, reported improved treatment convenience and satisfaction compared with VKA therapy. This pre-specified sub-study aimed to assess the impact of country and age on patients' perceptions of dabigatran or VKA therapy in AF. METHODS: RE-SONANCE was an observational, prospective, multi-national study (NCT02684981) that assessed treatment satisfaction and convenience in patients switching from VKAs to dabigatran (Cohort A), or newly diagnosed with AF receiving dabigatran or VKAs (Cohort B), using the PACT-Q questionnaire. Pre-specified exploratory outcomes: variation in PACT-Q2 scores by country and age (< 65, 65 to < 75, ≥ 75 years) (both cohorts); variation in PACT-Q1 responses at baseline by country and age (Cohort B). RESULTS: Patients from 12 countries (Europe/Israel) were enrolled in Cohort A (n = 4103) or B (n = 5369). In Cohort A, mean (standard deviation) PACT-Q2 score increase was highest in Romania (convenience: 29.6 [23.6]) and Hungary (satisfaction: 26.0 [21.4]) (p < 0.001). In Cohort B, mean (standard error) increase in PACT-Q2 scores between dabigatran and VKAs was highest in Romania (visit 3: 29.0 [1.3]; 24.5 [0.9], p < 0.001). Mean PACT-Q2 score increase by age (all p < 0.001) was similar across ages. PACT-Q1 responses revealed lowest expectations of treatment success in Romania and greatest concerns about payment in Estonia, Latvia, and Romania, but were similar across ages. CONCLUSIONS: Treatment satisfaction and convenience tended to favor dabigatran over VKAs. Regional differences in treatment expectations exist across Europe. TRIAL AND CLINICAL REGISTRY: Trial registration number: ClinicalTrials.gov NCT02684981. Trial registration date: February 18, 2016.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012006
003      
CZ-PrNML
005      
20220506130401.0
007      
ta
008      
220425s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11239-021-02450-2 $2 doi
035    __
$a (PubMed)33929686
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Vinereanu, Dragos $u University of Medicine and Pharmacy Carol Davila, University and Emergency Hospital, Bucharest, Splaiul Independentei 169, 050078, Bucharest, Romania. vinereanu@gmail.com
245    10
$a Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study / $c D. Vinereanu, D. Napalkov, J. Bergler-Klein, B. Benczur, M. Ciernik, N. Gotcheva, A. Medvedchikov, P. Põder, D. Simić, A. Skride, W. Tang, M. Trusz-Gluza, J. Vesely
520    9_
$a BACKGROUND: The oral anticoagulant dabigatran offers an effective alternative to vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF), yet patient preference data are limited. The prospective observational RE-SONANCE study demonstrated that patients with AF, newly initiated on dabigatran, or switching to dabigatran from long-term VKA therapy, reported improved treatment convenience and satisfaction compared with VKA therapy. This pre-specified sub-study aimed to assess the impact of country and age on patients' perceptions of dabigatran or VKA therapy in AF. METHODS: RE-SONANCE was an observational, prospective, multi-national study (NCT02684981) that assessed treatment satisfaction and convenience in patients switching from VKAs to dabigatran (Cohort A), or newly diagnosed with AF receiving dabigatran or VKAs (Cohort B), using the PACT-Q questionnaire. Pre-specified exploratory outcomes: variation in PACT-Q2 scores by country and age (< 65, 65 to < 75, ≥ 75 years) (both cohorts); variation in PACT-Q1 responses at baseline by country and age (Cohort B). RESULTS: Patients from 12 countries (Europe/Israel) were enrolled in Cohort A (n = 4103) or B (n = 5369). In Cohort A, mean (standard deviation) PACT-Q2 score increase was highest in Romania (convenience: 29.6 [23.6]) and Hungary (satisfaction: 26.0 [21.4]) (p < 0.001). In Cohort B, mean (standard error) increase in PACT-Q2 scores between dabigatran and VKAs was highest in Romania (visit 3: 29.0 [1.3]; 24.5 [0.9], p < 0.001). Mean PACT-Q2 score increase by age (all p < 0.001) was similar across ages. PACT-Q1 responses revealed lowest expectations of treatment success in Romania and greatest concerns about payment in Estonia, Latvia, and Romania, but were similar across ages. CONCLUSIONS: Treatment satisfaction and convenience tended to favor dabigatran over VKAs. Regional differences in treatment expectations exist across Europe. TRIAL AND CLINICAL REGISTRY: Trial registration number: ClinicalTrials.gov NCT02684981. Trial registration date: February 18, 2016.
650    _2
$a aplikace orální $7 D000284
650    _2
$a senioři $7 D000368
650    _2
$a antikoagulancia $x terapeutické užití $7 D000925
650    12
$a fibrilace síní $x komplikace $x diagnóza $x farmakoterapie $7 D001281
650    _2
$a dabigatran $x terapeutické užití $7 D000069604
650    _2
$a fibrinolytika $x terapeutické užití $7 D005343
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    12
$a cévní mozková příhoda $x farmakoterapie $7 D020521
650    _2
$a vitamin K $x antagonisté a inhibitory $7 D014812
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Napalkov, Dmitry $u I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
700    1_
$a Bergler-Klein, Jutta $u Department of Cardiology, University Clinic of Internal Medicine II, Medical University of Vienna, Vienna, Austria
700    1_
$a Benczur, Bela $u Balassa Janos County Hospital, Szekszárd, Hungary
700    1_
$a Ciernik, Martin $u Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria
700    1_
$a Gotcheva, Nina $u National Cardiology Hospital, Sofia, Bulgaria
700    1_
$a Medvedchikov, Alexey $u Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria
700    1_
$a Põder, Pentti $u North Estonia Medical Centre Foundation, Tallinn, Estonia
700    1_
$a Simić, Dragan $u Clinic of Cardiology, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
700    1_
$a Skride, Andris $u Pauls Stradins Clinical University Hospital, Riga Stradinš University, Riga, Latvia
700    1_
$a Tang, Wenbo $u Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA
700    1_
$a Trusz-Gluza, Maria $u Silesian Medical University, Katowice, Poland
700    1_
$a Vesely, Jiří $u Faculty of Medicine in Hradec Kralove, Charles University and Edumed s.r.o, Broumov, Czech Republic
773    0_
$w MED00007760 $t Journal of thrombosis and thrombolysis $x 1573-742X $g Roč. 52, č. 4 (2021), s. 1195-1206
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33929686 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130353 $b ABA008
999    __
$a ok $b bmc $g 1789551 $s 1163207
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 52 $c 4 $d 1195-1206 $e 20210430 $i 1573-742X $m Journal of thrombosis and thrombolysis $n J Thromb Thrombolysis $x MED00007760
GRA    __
$a N/A $p Boehringer Ingelheim GmbH
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace